Received Feb 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | B9279 | — |
Patient received second dose of Twinrix late; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 52-year-old female patient who received HAB (Twinrix) (batch number B9279, expiry date 12-SEP-2026) for prophylaxis. Previously administered products included Twinrix (received 1st dose of Twinrix on 6th May 2023 with batch number 2PG309 and expiry date 19th September 2025). On 09-JAN-2025, the patient received the 2nd dose of Twinrix. On 09-JAN-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Patient received second dose of Twinrix late). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-FEB-2025 The reporter contacted GlaxoSmithKline to report that a 52 year old female patient received a dose of Twinrix on 6th May, and the second one on 9th January 2025 They wanted to know how the second dose should have been administered. Patient received second dose of Twinrix late, which led to Drug dose administration interval too long. This case is linked with US2025023743, reported by same reporter; Sender's Comments: US-GSK-US2025023743:same reporter